Dendrite Announces Three-For-Two Stock Split.

MORRISTOWN, NJ--(BUSINESS WIRE)--Sept. 14, 1999--

Dendrite International, Inc. (NASDAQ/NMS:DRTE), the leading supplier of enterprise-wide sales force effectiveness solutions for the pharmaceutical and Consumer Packaged Goods (CPG) industries, today announced that its Board of Directors has approved a three-for-two split, to be effected as a stock dividend.

"This action reflects the Board's confidence in Dendrite's future prospects," said John Bailye, Chairman and CEO of Dendrite. "This is expected to result in a trading range for Dendrite stock that is likely to appeal to a broader spectrum of investors."

Shareholders of record as of the close of business on September 23, 1999 will receive one (1) additional share of the Company's common stock for every two (2) shares held on that date. The payment date for the stock dividend will be on October 7, 1999, and the common stock will begin trading post-split the day after the payment date. No action on the part of shareholders is required.

ABOUT DENDRITE

With a strong focus on outcomes in the Pharmaceutical and Consumer Package Goods (CPG) industries, Dendrite is a leading global provider of highly-specialized, integrated product and service offerings to support strategies for a sustained competitive advantage. Thousands of sales representatives and their managers in over 150 companies in 57 countries rely on Dendrite for a uniquely tailored combination of tools, information and skills to help them prepare for tomorrow's challenges and improve their sales success. The Company uses its highly specialized industry knowledge to develop modular software products that enhance sales force effectiveness. The products, combined with specifically tailored coaching and support services, focus sales representatives on improving their performance. With a global infrastructure as its foundation, Dendrite's commitment to unparalleled service has been the hallmark of the business and the basis of strong customer loyalty since the Company's inception.

Headquartered in Morristown, New Jersey, Dendrite employs over 1100 people all around the world. For more information, visit the Company's Web site: http://www.drte.com.

Note: Dendrite is a registered trademark of Dendrite International, Inc.

This press release contains statements that are forward-looking statements and discuss expectations about future events or outcomes with respect to Dendrite and its business, including statements regarding expected results for future periods. The forward-looking statements are based on a number of assumptions and involve risks and uncertainties and, accordingly, Dendrite's actual results may differ materially from the results discussed or implied by in such forward-looking statements. Factors that could cause actual results to differ from the results expressed or implied by these forward-looking statements include: (i) our dependence on the pharmaceutical industry; (ii) our exposure to significant fluctuations in our quarterly results, as a result of which we may not meet market expectations; (iii) our dependence on our major customers; (iv) our inability to successfully introduce new products or respond to technological change; and (v) increased competition which may result in price reductions and reduced demand for our products and services. For further discussion of these and other factors that could adversely affect Dendrite's financial condition and results of operations consult Dendrite's annual report on Form 10-K filed with the Securities and Exchange Commission.